fdl169
Small moleculeexperimental
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02359357)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1ccc2c(-c3cccc(F)c3)nn(CC(=O)N(C)c3ccc4nc(C)oc4c3)c(=O)c2c1- Mol. weight
- 486.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095180 ↗
Also known as
- fdl169
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03756922 | Phase 1 | Nov 27, 2018 | Flatley Discovery Lab LLC |
| NCT03527095 | Phase 1 | Apr 5, 2018 | Flatley Discovery Lab LLC |
| NCT03516331 | Phase 1 | Mar 7, 2018 | Flatley Discovery Lab LLC |
| NCT03424252 | Phase 1 | Dec 18, 2017 | Flatley Discovery Lab LLC |
| NCT03093714 | Phase 1 | Jul 1, 2017 | Flatley Discovery Lab LLC |
| NCT02767297 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2016 | Flatley Discovery Lab LLC, Queen's University, Belfast |
| NCT02680418 | Phase 1 | Dec 1, 2015 | Flatley Discovery Lab LLC, Simbec-Orion |
| NCT02359357 | Phase 1 | Jan 1, 2015 | Flatley Discovery Lab LLC, Simbec-Orion |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Flatley Discovery Lab LLC | Academic/Hospital | 8 | 8 | 2 | 2015 |
| Simbec-Orion | For profit | 2 | 0 | 1 | 2015 |
| Queen's University, Belfast | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1